Drug Trial Radar · NCT01242202
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients
Last checked: Nov 20, 2026Latest source record: May 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
113
Actual
Start
Oct 21, 2010
Primary completion
May 25, 2012
Study completion May 25, 2012
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Nov 16, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate long-term safety and efficacy after concomitant administration of ASP1941 and α-glucosidase inhibitor in Japanese patients with type 2 diabetes mellitus.
Conditions
- Type 2 Diabetes Mellitus
Interventions
ipragliflozinDrug
oral
alpha glucosidase inhibitorDrug
oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in HbA1cTime frame: baseline and 52 weeks
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Chūbu, Japan
Site not named
Hokkaido, Japan
Site not named
Kansai, Japan
Site not named
Kantou, Japan
Site not named
Kyushu, Japan
Site not named
Tōhoku, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.